ca 125
Recently Published Documents


TOTAL DOCUMENTS

2975
(FIVE YEARS 575)

H-INDEX

76
(FIVE YEARS 7)

2022 ◽  
Author(s):  
Shikha Rani ◽  
Alka Sehgal ◽  
Jasbinder Kaur ◽  
Dilpreet Kaur Pandher ◽  
RPS Punia

Abstract Introduction: Ovarian cancer is associated with high morbidity and mortality. This is due to the nonspecific symptoms and no effective screening methods. Currently CA 125 is used as a tumor biomarker for the diagnosis of ovarian cancer, but it has its own limitations. So, there is need for other tumor biomarkers for the diagnosis of ovarian cancer. To determine the diagnostic test characteristics of plasma osteopontin (OPN) in detecting ovarian malignancy and comparing its performance with carbohydrate antigen-125 (CA 125). Methods: This is a prospective cross-sectional diagnostic test evaluation. Women with adnexal mass detected by clinical or radiological examination were enrolled as suspected cases. Women who presented with other gynecological conditions were enrolled as controls. OPN and CA 125 levels were measured in all enrolled subjects. Results: Among 106 women enrolled, 26 were ovarian cancer, 31 had benign ovarian masses and 49 were controls. Median plasma CA 125 levels were higher in subjects with ovarian cancer (298 U/ml; IQR 84-1082 U/ml vs. 37.5U/ml; IQR 17.6-82.9U/ml; P<0.001).CA 125 sensitivity, specificity, positive and negative likelihood ratios were 88.5%, 61.3%,2.10 and 0.19 respectively. Median plasma OPN levels were higher in subjects with ovarian cancer (63.1 ng/ml; IQR 39.3-137 ng/ml vs. 27ng/ml; IQR 20-52ng/ml; P=0.001). Sensitivity, specificity, positive and negative likelihood ratios of OPN were 50%,87%,2.58 and 0.62, respectively. Conclusion: OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125.


2022 ◽  
Vol 19 (3) ◽  
pp. 26-30
Author(s):  
Thị Ngọc Bích Trần ◽  
Ngọc Thành Cao
Keyword(s):  
Ca 125 ◽  
Beta Hcg ◽  

Mục tiêu: Khảo sát giá trị CA-125, β-hCG và progesterone huyết thanh trong các trường hợp thai lạc chỗ. Đối tượng và phương pháp nghiên cứu: Nghiên cứu bệnh chứng trên 42 trường hợp thai lạc và 42 trường hợp thai trong tử cung được quản lý tại Bệnh viện Trường Đại học Y - Dược Huế từ 05/2019 đến 05/2020. Chẩn đoán xác định thai lạc chỗ dựa vào kết quả phẫu thuật và giải phẫu bệnh. Nhóm chứng là các trường hợp đơn thai phát triển bình thường trong tử cung, tương đồng tuổi thai. Nồng độ CA-125 và β-hCG, progesterone huyết thanh khảo sát theo các nhóm tuổi thai, < 6 tuần, 6 - 7 tuần, và ≥ 8 tuần. Kết quả: Nồng độ CA-125 ở nhóm thai lạc chổ là 23,8 U/ml (11,6 - 59,4), thấp hơn nhóm thai trong tử cung 70,1 U/ml (35,0 - 146,0), p < 0,001. Nồng độ β-hCG và progesterone ở nhóm thai lạc chỗ thứ tự là 2570,0 mUI/ml (42,8 - 94579,0) và 9,1 ng/ml (0,7 - 29,8), các giá trị này đều thấp hơn so với nhóm thai trong tử cung, tương ứng là 18357,5 mIU/ml (4622,0 - 157985,0) và 26,7 ng/ml (20,4 - 37,1), p < 0,001. Ở nhóm thai lạc chổ, nồng độ CA-125 không có sự khác biệt có ý nghĩa thống kê theo tuổi thai, ở nhóm < 6 tuần, 6 - 7 tuần và nhóm ≥ 8 tuần tương ứng là 23,2 U/ml (11,6 - 59,4), 23,6 U/ml (15,9 - 48,9) và 23,3 U/ml (20,5 - 32,8), p = 0,08. Trong khi đó, ở nhóm thai phát triển trong tử cung, nồng độ CA-125 tăng dần theo tuổi thai, nhóm < 6 tuần, 6 - 7 tuần và nhóm ≥ 8 tuần tương ứng 59,1 U/ml (35,0 - 83,3), 81,4 U/ml (75,7 - 90,1) và 101,1 U/ml (91,4 - 146,0), p = 0,02. Kết luận: Nồng độ CA-125 và β-hCG, progesterone thấp hơn trong thai lạc chỗ so với thai trong tử cung. Giá trị CA-125 thay đổi không đáng kể theo tuổi thai trong nhóm thai lạc chỗ.


2022 ◽  
Author(s):  
Patrícia Lourenço ◽  
Filipe M. Cunha ◽  
Catarina Elias ◽  
Catarina Fernandes ◽  
Isaac Barroso ◽  
...  

2022 ◽  
Vol 11 ◽  
Author(s):  
Chun-Xue Wu ◽  
Miao-Ling Chen ◽  
Hao Zhang ◽  
Jian-Jun Han

PurposeTo compare the feasibility and efficacy of radiofrequency ablation (RFA) combined with chemotherapy and chemotherapy alone in patients with ovarian cancer liver metastasis (OCLM).MethodsIn this retrospective study, a total of 60 patients diagnosed with OCLM between May 2015 to February 2017 were included. All patients with ovarian cancer received chemotherapy and primary cytoreductive surgery before. Thirty patients underwent RFA and chemotherapy, and thirty patients only took chemotherapy. The overall survival (OS), CA-125 levels, and serum AST and ALT levels were compared between the two groups.ResultsIn the RFA group, the 1-,2-, and 3-year OS rates after RFA were 93.3%, 80.0%, and 53.3%, respectively. Serum AST and ALT levels were both elevated after RFA (p=0.0004, p&lt;0.0001). In the chemotherapy group, the 1-,2-, and 3-year OS rates were 79.5%, 60.1%, and 42.1%, respectively. Levels of serum AST and ALT were stable. CA-125 levels for both groups were also available.ConclusionBased on our analysis of a single institution’s series of patients with OCLM, RFA could be a feasibly effective option in the management of OCLM.


2022 ◽  
Vol 29 ◽  
pp. 107327482110531
Author(s):  
Yu-yuan Ma ◽  
Han Wang ◽  
Wei-dong Zhao ◽  
Yi-Fan Li ◽  
Jing-jing Wang ◽  
...  

Background Breast cancer (BC), especially metastatic BC, is one of the most lethal diseases in women. CA 125 and CA 15-3 are commonly used indicators for diagnosis and prognosis of BC. Some serological indicators, such as lactate dehydrogenase (LDH) and C-reactive protein (CRP), can also be used to assess the prognosis and progression in BC. Methods Univariate Cox regression analysis and LASSO regression analysis were performed to identify prognostic factors and build prognostic models. We distributed the patients into 2 groups based on the median risk score, analyzed prognosis by Kaplan–Meier curve, and screened independent prognostic factors by multivariate Cox regression analysis. Result We identified 4 indicators-LDH, CRP, CA 15-3, and CA 125—related to the prognosis in BC and established a prognostic model. The high LDH group showed worse overall survival (OS) than low LDH group ( P = .017; hazard ratio (HR), 1.528; 95% confidence interval (CI), 1.055-2.215). The high CRP group showed worse OS than low CRP group ( P = .004; HR, 1.666; 95% CI, 1.143-2.429). The high CA153 group showed worse OS than low CA 15-3 group (P=.011; HR, 1.563; 95% CI, 1.075-2.274). The high CA 125 group showed worse OS than low CA 125 group ( P = .021; HR, 1.499; 95% CI, 1.031-2.181). The area under the curve for risk score was .824, Ki-67 was .628, age was .511, and grade was .545. Risk score was found to be an independent prognostic factor using multivariate Cox regression analysis. Conclusion We successfully established an optimization model by combining 4 prognosis-related indicators to assess the prognosis in patients with metastatic BC.


2021 ◽  
pp. 82-89
Author(s):  
I. D. Stasiv ◽  
V. M. Ryzyk

Properly diagnosed benign ovarian tumors are a condition for optimal treatment tactics. Qualitative assessment of signs detected by multiparametric ultrasound, including compression elastography, is highly effective in the differential diagnosis of benign ovarian tumors. Our study became especially relevant for women in the reproductive period, because the correct diagnosis influenced the choice of surgical treatment in order to preserve the ovarian reserve. A comprehensive radiological study of 51 women with benign ovarian tumors was performed. The age of patients averaged 37.3 ± 8.7 years. In the structure of benign ovarian tumors, the frequency of serous cystadenoma was 31.38%, serous superficial papillomas - 25.49%, mucinous cystadenoma - 17.65%, mature teratomas - 15.68%, fibroma - 9.8%. Ultrasound was performed on a HITACHI ALOCA ARIETTA 70 using a cavitary multifrequency sensor with a frequency of 7.5-10 mHz and a sector sensor with a frequency of 2-5 mHz. The article analyzes the detailed sonographic picture of these formations in B-mode, Doppler mode and compression sonoelastography mode. Color and energy Doppler mapping techniques, as well as pulsed Doppler mode, which gave a quantitative characterization of blood flow, were used to study blood vessels. Vessel localization was determined using color Doppler mapping, and detailed qualitative assessment of blood flow loci was determined using energy Doppler. For all types of benign ovarian formations, a qualitative feature was determined - elastotype on the Ueno scale and stiffness index - Strain Ratio (coefficient of deformation) - a quantitative indicator. It was found that serous and mucinous cystadenomas belong to 0 and I elastotype on the Ueno scale, the papillary component of serous superficial papillomas was mapped with I and II elastotype, fibroids mainly belonged to II and III elastotype, and mature teratomas - to IV end V elastotype. Quantitative deformation rate for all benign ovarian tumors ranged from 0,63 to 24,9. Thus, the cardiac index of stiffness in serous cystadenomas was 0.92 ± 0.46, and in mature teratomas - 16.7 ± 8.4. The increased density of the latter in comparison with other representatives of benign formations can be explained by the presence in their structure of such elements as fibroblasts, bundles of spindle-shaped cells and bundles of collagen fibers (fibroids), bone and cartilage (mature teratoma). In addition to all the above research methods, the mobile application IOTA ADNEX 2014 was used, which helped to calculate the risk of malignancy. This is a simple calculator, which loads the data of the ultrasound examination, the patient's age, the level of CA-125. Our results showed that ultrasound examination of ovarian tumors is an accurate and highly informative method for stratification of risks according to the O-RADS classification. For stratification and the ultrasound risk management system, the O-RADS system was guided by consensus guidance from the American College of Radiology, which reduces or eliminates ambiguity in the interpretation of data in ultrasound protocols and provides a more accurate definition of ovarian malignancy. The O-RADS working group includes 5 categories: O-RADS 0 - incomplete examination score, O-RADS 1 - normal unchanged premenopausal ovary, O-RADS 2 - almost always benign (risk of malignancy - <1%), O-RADS 3 - the presence of education with a low level of malignancy - from 1 to 10%, O-RADS 4 - medium risk of malignancy - from 10 to 50% and O-RADS 5 - education with a high level of malignancy -> 50%.


2021 ◽  
Vol 50 (3) ◽  
pp. 63-65
Author(s):  
B. L. Tsivyan ◽  
A. N. Maklyak ◽  
V. F. Bezhenar

The article deals with the new possibilities of laparoscopic technique in diagnosis and treatment of ovarian tumors. The authors elaborate the criteria of differential diagnostics of benign and malignant ovarian tumors at early stages. The research is based on the analysis of 222 cases of different ovarian tumors. The authors state the necessity of rational preoperative preparation and obligatory screening in patients with ovarian tumors before and after the operation with the use of tumor marker CA-125.


2021 ◽  
Vol 42 (1) ◽  
pp. 349-353
Author(s):  
JUHUN LEE ◽  
JONG MI KIM ◽  
YOON HEE LEE ◽  
GUN OH CHONG ◽  
DAE GY HONG

Author(s):  
Nasreen S. Badr ◽  
Samira Y. El Mallah ◽  
Magda I. El Mahdy ◽  
Hanaa F. Ahmad

Background: The aim of this study was to estimate the prognostic efficacy of repeated measurement of maternal serum CA125 in first trimester threatened miscarriage.Methods: Prospective case control study was conducted in the outpatient clinic. 100 pregnant women were divided into 50 women with normal course of pregnancy, and the other 50 were subdivided into 25 pregnant women with lower abdominal pain without vaginal bleeding and 25 presented with minimal vaginal bleeding. Repeated measuring of serum CA125 was done for each case on the 5th, 10th weeks of gestation.Results: Findings of this study suggested the possibility of using serum CA-125 for determining the prognosis of first trimester threatened miscarriage with cut-off value of CA125 38.25 U/ml on the 5th week of gestation and 53 U/ml on the 10th week of gestation in patients presented with pain only but in patients presented with minimal vaginal bleeding the cut-off value of CA125 on the 5th week of gestation become 45.6 U/ml and 68 U/ml on the 10th week of gestation.Conclusions: CA125, on its own, can discriminate between continued and non-continued pregnancy. 


Sign in / Sign up

Export Citation Format

Share Document